Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Willow Biosciences Inc., (“Willow”) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for
manufacturing a large volume anti-infective Active Pharmaceutical ...
read more
Thursday, December 19, 2019
WindMIL has entered into a research collaboration with Bristol-Myers Squibb to evaluate MILs in combination with Opdivo in patients with locally advanced unresectable or metastatic NSCLC.
read more
Tuesday, February 12, 2019
WuXi Biologics and Amicus Therapeutics announced that the companies have entered into an exclusive commercial manufacturing partnership for Amicus' Pompe biologic ATB200.
read more
Wednesday, January 31, 2024
WuXi Biologics announced the successful completion of the first manufacturing run at its drug substance facility MFG7, paving the way for large-scale commercial manufacturing projects at this Ireland site.
read more
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that its manufacturing subsidiary, Syn-The-All Pharmaceutical ...
read more
WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO) has added two 2,000 L reactors and a large-scale continuous purification system for peptide manufacturing at its Changzhou campus.
read more
STA Pharmaceutical announces that its API R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection for two APIs from the FDA – with no Form 483s issued.
read more
WuXi STA announced the opening of its large-scale oligonucleotide API manufacturing facility in Changzhou, China.
read more
STA Pharmaceutical announced its ASU in Shanghai and API process R&D and manufacturing facility in Changzhou, have successfully passed two inspections from the FDA.
read more
STA Pharmaceutical announced its partner, Ascletis has received approval from China Food and Drug Administration of its Category 1 new drug, Ganovo, to treat viral hepatitis C.
read more
STA Pharmaceutical, a subsidiary of WuXi AppTec, and Dizal Pharmaceutical have announced a strategic partnership.
read more
STA Pharmaceutical announces its API manufacturing facility at Jinshan has successfully passed its fourth inspection from the FDA – with no Form 483s issued.
read more
Wednesday, March 27, 2019
STA Pharmaceutical WuXi STA announces its new drug product manufacturing facility in Waigaoqiao Free Trade Zone of Shanghai has passed its first GMP inspection by the European MPA.
read more
STA Pharmaceutical, a WuXi AppTec group company, has merged with WuXi AppTec’s Pharmaceutical Development Services division.
read more
Tuesday, September 22, 2015
Xcelience and Powdersize announced today the addition of the Netzsch Delta Vita media mills, a nanoparticle milling solution, to their arsenal of capabilities. For the first time, one CDMO
can provide solutions for a full range of particle size ...
read more